Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited are not responsible for the contents of this announcement, make no representations as to its accuracy or completeness, and expressly disclaim any liability for any loss arising out of or in reliance on all or any part of this announcement.
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(Shenzhen Hepalink Pharmaceutical Group Co., Ltd.)
(A company limited by shares incorporated in the People's Republic of China)
(Stock Code: 9989)
This announcement is voluntarily published by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company", together with its subsidiaries referred to as the "Group") to inform the shareholders and potential investors of the Company about the latest developments in the Group's business.
The Board of Directors of the Company (the "Board") is pleased to announce that Novonox, a Enoxaparin sodium injection product produced by its wholly-owned subsidiary, Shenzhen Tiandao Pharmaceutical Co., Ltd., as a supplier, has been approved for marketing by the National Pharmacological Commission of Bolivia.
Basic information on medicines
(1) Drug brand: Novonox
(ii) Novonox (enoxaparin) is suitable for:
Prevention in patients with thromboembolic disease (deep vein thrombosis):
Surgical orthopedic surgery of the hip or knee joint; also suitable for the prevention of venous thrombosis during hospitalization after hip replacement or after discharge
High-risk abdominal, gynecological, or urinary surgery
Colorectal surgery
Medical prevention of deep vein thrombosis (DVT): patients with deep vein embolism above moderate risk;
Patients who are bedridden due to moderate to severe acute cardiac insufficiency (NYHA type III or IV heart failure) show acute respiratory failure or chronic respiratory insufficiency that does not require mechanical ventilation support, and acute respiratory infection that excludes septic shock requires short-term prevention of deep vein thrombosis.
Prevention of thrombosis during hemodialysis treatment.
Novonox is also suitable for:
* Treatment of deep vein thrombosis with or without pulmonary embolism,
*Treatment of unstable angina or myocardial infarction without Q wave changes can be combined with aspirin medication.
*Treatment of acute st-segment elevation myocardial infarction (STEMI), including medication and subsequent percutaneous coronary intervention (PCI) in patients.
(3) Dosage form: injection solution
(4) Specifications:
Novonox: 40mg/0.4ml, 60mg/0.6ml
(5) Registration classification: Prescription drugs
Benefits and implications for the Company
At present, the Group's enoxaparin sodium injection products have been approved for marketing in more than 50 countries around the world. The Board of Directors believes that the good feedback of sales and safety data in overseas markets over the past three years has allowed the Group to gain more market share, and the Board expects that the approval of the registration will further accelerate the global layout of the Company's formulation business.
This is hereby announced.
Undertake the orders of the Board of Directors
Shenzhen Hepalink Pharmaceutical Group Co., Ltd
Chairman
Li Li
Shenzhen, China
June 7, 2021
As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin, and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.